A Phase I, Randomized, Double-blind, Single-dose, Partial Replicate, 3-way Cross-over Study to Assess the Total Systemic Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA in Healthy Adult Participants
Latest Information Update: 12 Jun 2025
At a glance
- Drugs Budesonide (Primary) ; Formoterol; Glycopyrrolate
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 05 Jun 2025 Status changed from active, no longer recruiting to completed.
- 25 May 2025 Planned End Date changed from 30 Jun 2025 to 2 Jun 2025.
- 25 May 2025 Planned primary completion date changed from 30 Jun 2025 to 2 Jun 2025.